Opinion on Therapy Area in South and Central America

Published within

« | ... | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | » »|

Type Product title / description Pub Price
Expert View
Expert View

ACR 2009: Benlysta outshines disappointing rheumatoid arthritis data

Datamonitor recently attended this year's American College of Rheumatology Annual Conference in Philadelphia. No ground-breaking data for rheumatoid arthritis therapies were presented; instead, systemic lupus erythematosus stole the limelight. Human Genome Sciences' Benlysta in particular generated a stir, being the first drug in this indication to generate positive data at Phase III.

Published By Datamonitor
23 Oct 2009
CommentWire
CommentWire

Abbott: safeguarding market leadership through elagolix deal

Global healthcare firm Abbott has boosted its gonadotropin releasing hormones pipeline through a deal with Neurocrine for the continued development of new promising candidate elagolix. The partnership is favorable for both parties, with Abbott seeking to maintain its endometriosis market leadership after Lupron's patent expiry in 2014.

Published By Datamonitor
17 Jun 2010
Expert View
Expert View

AAN 2010: spotlight shines on Novartis' and Merck KGaA's oral MS candidates

Datamonitor attended this year's American Academy of Neurology conference, where developments in multiple sclerosis took precedence for the third consecutive year. Both Novartis and Merck KGaA presented new data for their pipeline candidates, while Acorda used the meeting as a platform to share data for its symptomatic treatment Ampyra, which was recently approved by the FDA.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2010: new treatments address unmet needs in Alzheimer's and epilepsy

A number of leading drug makers used this year's meeting of the American Academy of Neurology to present new data for promising pipeline candidates. Despite promising results, however, Datamonitor believes that the epilepsy drugs will struggle to find their place in the market. Moreover, the positive Phase II data for Baxter's potential Alzheimer's therapy Gammagard do not guarantee later success.

Published By Datamonitor
20 Apr 2010
Expert View
Expert View

AAN 2010: late-stage pipeline candidates take center stage in migraine

In the wake of Imitrex's and Topamax's patent expiries, announcements at this year's American Academy of Neurology meeting focused firmly on the next major breakthroughs for the acute and prophylactic migraine markets. Pooled data for candidates from Allergan and Merck & Co demonstrated impressive potential, suggesting renewed hope for sufferers.

Published By Datamonitor
20 Apr 2010

« | ... | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | » »|

No help is available.